炎症性肠病中的肠道微生物点:目前的位置和未来的发展
Naveen Sivakumar1, Ashwin Krishnamoorthy2, Harshita Ryali3
1Institute of Precision Diagnostics & Translational Medicine, University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, UK.
Biomedicines
|March 28, 2025
概括
针对炎症性肠病 (IBD) 的新型非手术治疗方法显示出有前途. 肠道微生物组和基因疗法的研究为人类试验中更安全,更有针对性的治疗提供了潜力.
科学领域:
- 胃肠道学和免疫学
- 翻译医学是一种翻译医学.
背景情况:
- 炎症性肠道疾病 (IBD) 的管理通常涉及作为最后手段的手术,带有重大风险.
- 新兴疗法旨在调节IBD患者的宿主免疫反应.
研究的目的:
- 审查2024年3月至2025年2月期间发表的IBD新型非手术治疗方法.
- 专注于肠道微生物组和IBD的基因疗法的进展.
主要方法:
- 从2024年3月到2025年2月,对IBD治疗的文献综述.
- 重点是关于肠道微生物组和基因治疗应用的研究.
主要成果:
- 新型疗法在安全性和受欢迎程度上不断增加.
- 动物研究表明益生菌疗法有希望的结果,有可能在FDA批准后进行人体试验.
- 针对性抗炎方法在临床前模型中显示出有效性.
结论:
- 有希望的诊断方法和新的治疗方法正在出现IBD.
- 临床前研究表明,针对特定炎症部位的安全和可转移的治疗策略.
- 免疫应答调节为未来IBD研究提供了可行和安全的治疗途径.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Dysbiosis of the Gut Microbiota
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...


